



For further information:
Consuelo Trillo Díaz
ctrillo@rovi.es
Tel: + 34 91 244 44 10

INCORPORATION OF TWO DOCTORS TO THE R&D&i WITHIN THE "TORRES QUEVEDO" PROGRAM 2020 CALL

Madrid – 30 of October 2020

ROVI is a company committed to innovation, this enables it to safeguard its portfolio, composed by over 500 patent dossiers, 408 of which have now been granted, while 96 are in the examination and evaluation phase. Currently, R&D projects of ROVI are mainly focused in glycomics and ISM[®] platform, the latter is a drug release system, owned by ROVI, whose objective is improving patient's adherence to treatment.

ROVI has received the support of the Ministry of Economy and Competitiveness in its Research and Development work through the TORRES QUEVEDO program. This program promotes the recruitment of doctors to develop industrial research projects, experimental development or feasibility studies, in order to promote the professional career of investigators, as well as to stimulate demand, in the private sector, of well trained personnel to undertake R&D plans and projects, and help to consolidate newly created technological companies.

Thanks to the funding received, the staff has been strengthened through the recruitment of two university doctors for the implementation of the R&D&i activity within the framework of the projects **"Project to improve the purification process in low molecular weight heparins"** y **"Letrozole clinical developmen ISM[®]"**, Reference nº. of files: **PTQ-2019-010712 Y PTQ-2019-010542**.



About ROVI

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy France and Poland, and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, which is already marketed in 56 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its in-house developed enoxaparin biosimilar in Europe. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es.